Granted Patent
B2
US 12,708,619 · App. 17/967,415 · Granted Aug 18, 2026
Use of pridopidine for treating anxiety and depression
Assignee:
Prilenia Neurotherapeutics Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
This invention provides a method of treating depression or anxiety in a human subject by administering a composition comprising pridopidine or a pharmaceutically acceptable salt thereof.
Claims (12)
1 . A method of treating depression or anxiety in a human subject by administering a composition comprising an amount of pridopidine, or a pharmaceutically acceptable salt thereof.
2 . The method of claim 1 , wherein the depression or anxiety is not caused by Huntington's Disease.
3 . The method of claim 1 , wherein the depression or anxiety is associated with cognitive deficits.
4 . The method of claim 2 , wherein the depression or anxiety is associated with cognitive deficits.
5 . The method of claim 3 , wherein the cognitive deficits comprise memory loss, loss of higher reasoning, forgetfulness, learning disabilities, concentration difficulties, or decreased intelligence.
6 . The method of claim 4 , wherein the cognitive deficits comprise memory loss, loss of higher reasoning, forgetfulness, learning disabilities, concentration difficulties, or decreased intelligence.
7 . The method of claim 1 , wherein the composition comprises between 22.5 mg/day and 315 mg/day of pridopidine or pharmaceutically acceptable salt thereof.
8 . The method of claim 1 , wherein the composition is administered once daily or twice daily.
9 . The method of claim 1 , wherein the composition is administered orally.
10 . The method of claim 1 , wherein the pharmaceutically acceptable salt of pridopidine comprises pridopidine hydrochloride, hydrobromide, nitrate, perchlorate, phosphate, sulphate, formate, acetate, aconate, ascorbate, benzenesulphonate, benzoate, cinnamate, citrate, embonate, enantate, fumarate, glutamate, glycolate, lactate, maleate, malonate, mandelate, methanesulphonate, naphthalene-2-sulphonate, phthalate, salicylate, sorbate, stearate, succinate, tartrate or toluene-p-sulphonate salt.
11 . The method of claim 10 , wherein the salt comprises hydrochloride salt.
12 . The method of claim 1 , wherein the composition comprises an amount of pridopidine base.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 30, 2022
From: HAYDEN, MICHAEL; GEVA, MICHAL
To: PRILENIA NEUROTHERAPEUTICS LTD.
Reel/Frame 061915/0115 →
Continuity (7)
Continuation In Part
PCTIL2022051082
· Oct 11, 2022
Provisional Application
62186221
· Jun 29, 2015
Provisional Application
62120771
· Feb 25, 2015
Related Publication
20230112948A1
· Apr 13, 2023
References Cited (214)
US 5321012A
· Mayer et al.
· 1994
[cited by applicant]
US 5462947A
· Svensson et al.
· 1995
[cited by applicant]
US 6114319A
· Kimura et al.
· 2000
[cited by applicant]
US 6903120B2
· Sonesson et al.
· 2005
[cited by applicant]
US 7417043B2
· Sonesson et al.
· 2008
[cited by applicant]
US 7579474B2
· Sonesson et al.
· 2009
[cited by applicant]
US 7923459B2
· Gauthier et al.
· 2011
[cited by applicant]
US 8680042B2
· Bogdanova et al.
· 2014
[cited by applicant]
US 8809302B2
· Cohen et al.
· 2014
[cited by applicant]
US 8835438B2
· Ishiyama
· 2014
[cited by applicant]
US 9006445B2
· Sonesson et al.
· 2015
[cited by applicant]
US 9012476B2
· Zimmermann et al.
· 2015
[cited by applicant]
US 9139525B2
· Wikstrom
· 2015
[cited by applicant]
US 9163011B2
· Lueoend et al.
· 2015
[cited by applicant]
US RE46117E
· Sonesson et al.
· 2016
[cited by applicant]
US 9718805B2
· Besidski et al.
· 2017
[cited by applicant]
US 9796673B2
· Wu et al.
· 2017
[cited by applicant]
US 9814706B2
· Zimmermann et al.
· 2017
[cited by applicant]
US 20070238878A1
· Desmond et al.
· 2007
[cited by applicant]
US 20100048509A1
· Kovacic et al.
· 2010
[cited by applicant]
US 20100105736A1
· Wikström
· 2010
[cited by applicant]
US 20100197712A1
· Carlsson et al.
· 2010
[cited by applicant]
US 20110206782A1
· Zhang
· 2011
[cited by applicant]
US 20130065966A1
· Navarro Medrano et al.
· 2013
[cited by applicant]
US 20130150406A1
· Zimmermann et al.
· 2013
[cited by applicant]
US 20130197031A1
· Sonesson
· 2013
[cited by applicant]
US 20130267552A1
· Waters et al.
· 2013
[cited by applicant]
US 20140088140A1
· Hayden et al.
· 2014
[cited by applicant]
US 20140088144A1
· Egan
· 2014
[cited by applicant]
US 20140088145A1
· Hayden et al.
· 2014
[cited by applicant]
US 20150202302A1
· Licht et al.
· 2015
[cited by applicant]
US 20150209346A1
· Hayden et al.
· 2015
[cited by applicant]
US 20150216850A1
· Hayden et al.
· 2015
[cited by applicant]
US 20150374677A1
· Schmidt
· 2015
[cited by applicant]
US 20160095847A1
· Sonesson
· 2016
[cited by applicant]
US 20160166559A1
· Sonesson
· 2016
[cited by applicant]
US 20170020854A1
· Licht et al.
· 2017
[cited by applicant]
US 20170266170A1
· Waters et al.
· 2017
[cited by applicant]
US 20180055832A1
· Hayden et al.
· 2018
[cited by applicant]
US 20180235950A1
· Sonesson
· 2018
[cited by applicant]
US 20190015401A1
· Sonesson
· 2019
[cited by applicant]
US 20190046516A1
· Russ et al.
· 2019
[cited by applicant]
US 20190192496A1
· Hayden et al.
· 2019
[cited by applicant]
US 20190209542A1
· Licht et al.
· 2019
[cited by applicant]
US 20190350915A1
· Bassan et al.
· 2019
[cited by applicant]
US 20200030308A1
· Schmidt et al.
· 2020
[cited by applicant]
US 20210220342A1
· Hayden et al.
· 2021
[cited by applicant]
US 20220023280A1
· Schmidt et al.
· 2022
[cited by applicant]
US 20220062255A1
· Geva et al.
· 2022
[cited by applicant]
WO WO1999003470A1
· 1999
[cited by applicant]
WO WO2001046144A1
· 2001
[cited by applicant]
WO WO0146145A1
· 2001
[cited by examiner]
WO WO2001046145A1
· 2001
[cited by applicant]
WO WO2005121092
· 2005
[cited by applicant]
WO WO2006040155A1
· 2006
[cited by applicant]
WO WO2008127188A1
· 2008
[cited by applicant]
WO WO2008155357
· 2008
[cited by applicant]
WO WO2009074607A1
· 2009
[cited by applicant]
WO WO2011054759A1
· 2011
[cited by applicant]
WO WO2011107583A1
· 2011
[cited by applicant]
WO WO2012002863A1
· 2012
[cited by applicant]
WO WO2012028635A1
· 2012
[cited by applicant]
WO WO2013027188A1
· 2013
[cited by applicant]
WO WO2013034622A1
· 2013
[cited by applicant]
WO WO2013086425A1
· 2013
[cited by applicant]
WO WO2013152105A1
· 2013
[cited by applicant]
WO WO2014195322A1
· 2014
[cited by applicant]
WO WO2014205229A1
· 2014
[cited by applicant]
WO WO2015112601A1
· 2015
[cited by applicant]
WO WO2016003919A1
· 2016
[cited by applicant]
WO WO2016138130A1
· 2016
[cited by applicant]
WO WO2016138135A1
· 2016
[cited by applicant]
WO WO2017015609A1
· 2017
[cited by applicant]
WO WO2017015615A1
· 2017
[cited by applicant]
WO WO2017048457A1
· 2017
[cited by applicant]
WO WO2017147366A1
· 2017
[cited by applicant]
WO WO2018039475A1
· 2018
[cited by applicant]
WO WO2018039477A1
· 2018
[cited by applicant]
WO WO2020188558A1
· 2020
[cited by applicant]
WO WO2022107146A1
· 2022
[cited by applicant]
Bermack, Jordanna E.; Debonnel, Guy. The role of sigma receptors in depression. Journal of pharmacological sciences, 2005, 97.3: 317-336.
[cited by applicant]
Pubchem, U.S. National Library of medicine, (Oct. 11, 2011), Database accession No. CID53379489, XP002775774, 2010.
[cited by applicant]
A multiple-ascending dose study of pridopidine in healthy volunteers (2012). Trial Profile Adis Insight Springer (Table of Contents) (http : //adis insight'. springer .com/trials/700207057).
[cited by applicant]
Agosta, F. et al. (2012). Resting state fMRI in Alzheimer's disease: Beyond the default mode network.
[cited by applicant]
Ammar, I. H. et al. (2011). The effects on motor behaviour and short-term memory tasks in mice following an acute administration of Mitragyna speciosa alkaloid extract and mitragynine.
[cited by applicant]
Ates-Alagoz, Z. et al. (2013). NMDA receptor antagonists for treatment of depression.
[cited by applicant]
Austin, M. P. et al. (2001). Cognitive deficits in depression: possible implications for functional neuropathology.
[cited by applicant]
Balthazar, M. et al. (2014). Alzheimer as a Default Mode Network Disease: A Grey Matter, Functional and Structural Connectivity Study. Alzheimer's & Dementia, 10(4), p. 391.
[cited by applicant]
Barendse, E. M. et al. (2013). Working memory deficits in high-functioning adolescents with autism spectrum disorders: neuropsychological and neuroimaging correlates.
[cited by applicant]
Bartoszyk, G. D. (1998). Anxiolytic effects of dopamine receptor ligands: I. Involvement of dopamine autoreceptors.
[cited by applicant]
Bartoszyk, G. D. et al.(1997). EMD 68843, a serotonin reuptake inhibitor with selective presynaptic 5-HT1A receptor agonistic properties.
[cited by applicant]
Bech, P. (2022). Rating scales in depression: limitations and pitfalls.
[cited by applicant]
Bech, P et al. (2001). The sensitivity and specificity of the Major Depression Inventory, using the Present State Examination as the index of diagnostic validity.
[cited by applicant]
Bonnelle, V. et al. (2012). Salience network integrity predicts default mode network function after traumatic brain injury.
[cited by applicant]
Bourne, J. N. et al. (2008). Balancing structure and function at hippocampal dendritic spines.
[cited by applicant]
Brier, M. R. et al. (2014). Network dysfunction in Alzheimer's disease: refining the disconnection hypothesis.
[cited by applicant]
Broekkamp, C. L. et al. (1986). Major tranquillizers can be distinguished from minor tranquillizers on the basis of effects on marble burying and swim-induced grooming in mice.
[cited by applicant]
Bryan, K. J. et al. (2009). Chapter 1—Transgenic mouse models of Alzheimer's disease: behavioral testing and considerations.
[cited by applicant]
Buckner, R. L. et al. (2008). The brain's default network: anatomy, function, and relevance to disease.
[cited by applicant]
Callizot, N. et al. (2013). Operational dissection of β-amyloid cytopathic effects on cultured neurons.
[cited by applicant]
Carlsson Research (2006) “Carlsson Research Reports Positive Effects of ACR16 in Huntington Disease Phase II Study” Press Release.
[cited by applicant]
Cognition—Definition of Cognition by Oxford Online Dictionary.
[cited by applicant]
Combs, C. K. et al. (2000). Inflammatory mechanisms in Alzheimer's disease: inhibition of β-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARγ agonists.
[cited by applicant]
Connor, K. M. et al. (2000). Psychometric properties of the Social Phobia Inventory (SPIN): New self-rating scale.
[cited by applicant]
Coyle, J. T. et al. (1983). Alzheimer's disease: a disorder of cortical cholinergic innervation.
[cited by applicant]
Cumming, T. B. et al. (2013). Stroke, cognitive deficits, and rehabilitation: still an incomplete picture.
[cited by applicant]
Cummings, J. L. et al. (1998). Alzheimer's disease: etiologies, pathophysiology, cognitive reserve, and treatment opportunities.
[cited by applicant]
Dahlen Patrik (2011). NeuroSearch provides update on the Huntexil® development programme and plans a comprehensive restructuring of the company's operations.
[cited by applicant]
Danysz, W. et al. (2003). The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence.
[cited by applicant]
De Tommaso, M. et al. (2004). Effects of rivastigmine on motor and cognitive impairment in Huntington's disease.
[cited by applicant]
De Yebenes, J. G. et al. (2011). Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial.
[cited by applicant]
Detrait, E., et al. (2010). Automation of continuous spontaneous alternation to increase the throughput for in vivo screening of cognitive enhancers. Optimization of the ethovision system for the Y-maze test in mice.
[cited by applicant]
Dietz, D. M. et al. (2014). AFosB induction in prefrontal cortex by antipsychotic drugs is associated with negative behavioral outcomes.
[cited by applicant]
Dubinsky, R. et al. (2010). Third Annual Huntington Disease Clinical Research Symposium.
[cited by applicant]
Dubois, B. et al. (1996). Cognitive deficits in Parkinson's disease.
[cited by applicant]
Dyhring, T. et al. (2010). The dopaminergic stabilizers pridopidine (ACR16) and (−)-OSU6162 display dopamine D2 receptor antagonism and fast receptor dissociation properties.
[cited by applicant]
Extended European Search Report dated Jul. 6, 2018 issued for the corresponding patent application No. 16756274.3.
[cited by applicant]
Extended European Search Report dated Nov. 12, 2019 issued for the corresponding patent application No. 19191835.8.
[cited by applicant]
Extneded European Search Report dated Jun. 24, 2021 issued for the corresponding patent application No. EP21153340.1.
[cited by applicant]
Ferreri, F. et al. (2011). Current research on cognitive aspects of anxiety disorders.
[cited by applicant]
Fioravanti, M. et al. (2012). Cognitive deficits in schizophrenia: an updated metanalysis of the scientific evidence.
[cited by applicant]
Foroud, T. et al. (1995). Cognitive scores in carriers of Huntington's disease gene compared to noncarriers.
[cited by applicant]
Francardo, V. et al. (2014). Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism.
[cited by applicant]
Geva, M. et al. (2016). Pridopidine activates neuroprotective pathways impaired in Huntington Disease.
[cited by applicant]
Ghosh, B. C. et al. (2012). Social cognitive deficits and their neural correlates in progressive supranuclear palsy.
[cited by applicant]
Girardi, A. et al. (2011). Deficits in emotional and social cognition in amyotrophic lateral sclerosis.
[cited by applicant]
Gould, T. J. (2010). Addiction and cognition.
[cited by applicant]
Grachev, I. D. et al. (2021). Sigma-1 and dopamine D2/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: a [18F] fluspidine and [18F] fallypride PET study.
[cited by applicant]
Graveland, G. A. et al. (1985). Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease.
[cited by applicant]
Grunblatt, E. et al. (1999). Potent neuroprotective and antioxidant activity ofapomorphine in MPTP and 6-hydroxydopamine induced neurotoxicity.
[cited by applicant]
Guye, M. et al. (2010). Graph theoretical analysis of structural and functional connectivity MRI in normal and pathological brain networks.
[cited by applicant]
Hamilton, M. A. X. (1959). The assessment of anxiety states by rating.
[cited by applicant]
Hart, R. P. et al. (2003). Cognitive impairment in patients with chronic pain: the significance of stress.
[cited by applicant]
Hironaka, N. et al. (2001). Memory-related acetylcholine efflux from rat prefrontal cortex and hippocampus: a microdialysis study.
[cited by applicant]
Huang, Y. C. et al. (2011). Increased prothrombin, apolipoprotein A-IV, and haptoglobin in the cerebrospinal fluid of patients with Huntington's disease.
[cited by applicant]
Huntington Study Group Hart Investigators. (2013). A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease.
[cited by applicant]
Jacqmin-Gadda, H. et al. (1997). A 5-year longitudinal study of the Mini-Mental State Examination in normal aging.
[cited by applicant]
Johansson, B. et al. (2012). Placebo-controlled cross-over study of the monoaminergic stabiliser (−)-OSU6162 in mental fatigue following stroke or traumatic brain injury.
[cited by applicant]
Johnston, T. H. et al. (2019). Pridopidine, a clinic-ready compound, reduces 3, 4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques.
[cited by applicant]
Jonkers, N. et al. (2000). MK801 influences L-DOPA-induced dopamine release in intact and hemi-parkinson rats.
[cited by applicant]
Julian, L. J. (2011). Measures of anxiety.
[cited by applicant]
Kalia, L. V. et al. (2008). NMDA receptors in clinical neurology: excitatory times ahead.
[cited by applicant]
Kalueff, A. V. et al. (2005). Mouse grooming microstructure is a reliable anxiety marker bidirectionally sensitive to GABAergic drugs.
[cited by applicant]
Katz, D. M. (2014). Brain-derived neurotrophic factor and Rett syndrome.
[cited by applicant]
Kawahara, M. et al. (2000). Molecular mechanism of neurodegeneration induced by Alzheimer's β-amyloid protein: channel formation and disruption of calcium homeostasis.
[cited by applicant]
Keefe, R. S. et al. (2014). Cognitive effects of pharmacotherapy for major depressive disorder: a systematic review.
[cited by applicant]
Kipps, C. M. et al. (2006). Theory of mind in frontotemporal dementia.
[cited by applicant]
Krabbendam, L. et al. (2000). Tardive dyskinesia is associated with impaired retrieval from long-term memory: the Curacao Extrapyramidal Syndromes Study: IV.
[cited by applicant]
Kreitzer, A. C. et al. (2008). Striatal plasticity and basal ganglia circuit function.
[cited by applicant]
Lanctot, K. L., et al. (2004). GABAergic function in Alzheimer's disease: evidence for dysfunction and potential as a therapeutic target for the treatment of behavioural and psychological symptoms of dementia.
[cited by applicant]
Landwehrmeyer, B. et al. (2011). Effects of the dopaminergic stabilizer pridopidine on motor symptoms in Huntington's disease: a meta-analysis.
[cited by applicant]
Leary, M. R. (1983). Social anxiousness: The construct and its measurement.
[cited by applicant]
Lucas-Jimenez, O et al. (2016). Altered functional connectivity in the default mode network is associated with cognitive impairment and brain anatomical changes in Parkinson's disease.
[cited by applicant]
Luszczki, J. J. et al. (2005). Pharmacological and behavioral characteristics of interactions between vigabatrin and conventional antiepileptic drugs in pentylenetetrazole-induced seizures in mice: an isobolographic ana…
[cited by applicant]
Marder, K. et al. (2000). Rate of functional decline in Huntington's disease.
[cited by applicant]
Mason, S. L et al. (2010). Cognitive follow up of a small cohort of Huntington's disease patients over a 5 year period.
[cited by applicant]
Maurice, T. et al. (1997). SA4503, A novel cognitive enhancer with σ1 receptor agonist properties, facilitates NMDA receptor-dependent learning in mice.
[cited by applicant]
Mckhann, G. et al. (1984). Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.
[cited by applicant]
Mckhann, G. M. et al. (2011). The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's diseas…
[cited by applicant]
Mevel, K. et al. (2011). The default mode network in healthy aging and Alzheimer's disease.
[cited by applicant]
Michl, M. et al. (2013). Pridopidine in the pharmacological treatment of Huntington's disease.
[cited by applicant]
Millter M. (2006). Swedish Company Announces Results of Phase II study of Dopamine Stabilizing Compound. Huntington's Disease Advocacy Center 2006 http://www.hdac.org/features/article.php?p articleNumber=254.
[cited by applicant]
Mohan, A. et al. (2016). Focus: the aging brain: the significance of the default mode network (DMN) in neurological and neuropsychiatric disorders: a review.
[cited by applicant]
Mostert, J. P. et al. (2008). Therapeutic potential of fluoxetine in neurological disorders.
[cited by applicant]
Nasreddine, Z. S. et al. (2005). The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment.
[cited by applicant]
NeuroSearch (2012). NeuroSearch A/S reports conclusions from the Multiple Ascending Dose study (MAD) with Huntexil®.
[cited by applicant]
NeuroSearch and Fleming Pederson (2010). NeuroSearch announces positive top-line results from Phase III Huntexil® study in Huntington's disease, the MermaiHD study.
[cited by applicant]
Neurosearch and Patrik Dahlen (2011). NeuroSearch provides update on the Huntexil® development programme and plans a comprehensive restructuring of the company's operations.
[cited by applicant]
Nguyen, L. et al. (2015). Role of sigma-1 receptors in neurodegenerative diseases.
[cited by applicant]
Nilsson, M. et al. (2004). The dopaminergic stabiliser ACR16 counteracts the behavioural primitivization induced by the NMDA receptor antagonist MK-801 in mice: implications for cognition.
[cited by applicant]
Onaolapo, O. J. et al. (2012). Elevated plus maze and Y-Maze behavioral effects of subchronic, oral low dose monosodium glutamate in swiss albino mice.
[cited by applicant]
Osterberg, O. (2013). A single-center, randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, and pharmacokinetics of multiple-ascending doses of pridopidine in healthy volunteers. Neur…
[cited by applicant]
Osterberg, O. et al. (2012) A single center randomized placebo controlled double-blind study to evaluate the safety. Presented at sixth Annual Huntington Disease Clinical Research Symposium, Seattle Washington USA.
[cited by applicant]
Parada-Turska, J. et al. (1990). Excitatory amino acid antagonists and memory: effect of drugs acting at N-methyl-D-aspartate receptors in learning and memory tasks.
[cited by applicant]
Parent, M. B. et al. (2004). Septohippocampal acetylcholine: involved in but not necessary for learning and memory?.
[cited by applicant]
Petrella, J. R. et al. (2011). Default mode network connectivity in stable vs progressive mild cognitive impairment.
[cited by applicant]
Pettersson, F. et al. (2010). Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl) phenyl]-1-prop…
[cited by applicant]
Pike, C. J. et al. (1991). In vitro aging of B-amyloid protein causes peptide aggregation and neurotoxicity.
[cited by applicant]
Rabinovich-Guilatt, L. et al. (2016). The effect of mild and moderate renal impairment on the pharmacokinetics of pridopidine, a new drug for Huntington's disease.
[cited by applicant]
Rapaport, M. H. (2009). Future drugs for the treatment of depression: the need to look beyond monoamine systems.
[cited by applicant]
Reading, P. J. et al. (2001). Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial.
[cited by applicant]
Remington's Pharmaceutical Sciences, 17th ed.
[cited by applicant]
Rosler, M. et al. (1999). Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial Commentary: Another piece of the Alzheimer's jigsaw.
[cited by applicant]
Rung, J. P. et al. (2005). The dopaminergic stabilizers (−)-OSU6162 and ACR16 reverse (+)-MK-801-induced social withdrawal in rats.
[cited by applicant]
Rung, J. P. et al. (2011). Effects of the dopamine stabilizers (S)-(−)-OSU6162 andACR16 on prolactin secretion in drug-naive and monoamine-depleted rats.
[cited by applicant]
Sahlholm, K. et al. (2013). The dopamine stabilizers ACR16 and (−)-OSU6162 display nanomolar affinities at the σ-1 receptor.
[cited by applicant]
Sahlholm, K. et al. (2015). Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses.
[cited by applicant]
Sakono, M. et al. (2012). Amyloid oligomer detection by immobilized molecular chaperone. Biochemical engineering journal, 61, 28-33.
[cited by applicant]
Sambataro, F. et al. (2010). Age-related alterations in default mode network: impact on working memory performance.
[cited by applicant]
Saunders, J. A. et al. (2012). NMDA antagonist MK801 recreates auditory electrophysiology disruption present in autism and other neurodevelopmental disorders.
[cited by applicant]
Seibenhener, M. L. et al. (2015). Use of the open field maze to measure locomotor and anxiety-like behavior in mice. JoVE—
[cited by applicant]
Seo, J. S. et al. (1997). Effect of MK-801 on the Prevention and Treatment of Tardive Dyskinesia. Korean Journal of Biological Psychiatry, 4(2), 246-250.
[cited by applicant]
Sisodia, S. S. et al. (1990). Evidence that β-amyloid protein in Alzheimer's disease is not derived by normal processing.
[cited by applicant]
Squitieri, F. et al. (2013). One-year safety and tolerability profile of pridopidine in patients with Huntington disease.
[cited by applicant]
Squitieri, F. et al. (2015). Profile of pridopidine and its potential in the treatment of Huntington disease: the evidence to date.
[cited by applicant]
Stafstrom, C. E. et al. (1997). Acute effects of MK801 on kainic acid-induced seizures in neonatal rats.
[cited by applicant]
Steen, R. G. et al. (2005). Cognitive deficits in children with sickle cell disease.
[cited by applicant]
Steimer, T. (2011). Animal models of anxiety disorders in rats and mice: some conceptual issues.
[cited by applicant]
Stout, J. C. et al. (2014). HD-CAB: A cognitive assessment battery for clinical trials in Huntington's disease1, 2, 3.
[cited by applicant]
Strik, J. J. et al. (2001). Sensitivity and specificity of observer and self-report questionnaires in major and minor depression following myocardial infarction.
[cited by applicant]
Tedroff, J. et al. (1999). Long-lasting improvement following (−)-OSU6162 in a patient with Huntington's disease.
[cited by applicant]
Treit, D. (1985). Animal models for the study of anti-anxiety agents: a review.
[cited by applicant]
Treit, D. et al. (1981). Conditioned defensive burying: a new paradigm for the study of anxiolytic agents.
[cited by applicant]
Trung, J. et al. (2019). Transcranial magnetic stimulation improves cognition over time in Parkinson's disease.
[cited by applicant]
Van Den Buuse, M. et al. (2005). Importance of animal models in schizophrenia research.
[cited by applicant]
Van Rijckevorsel, K. (2006). Cognitive problems related to epilepsy syndromes, especially malignant epilepsies.
[cited by applicant]
Winkler, J. et al. (1995). Essential role of neocortical acetylcholine in spatial memory.
[cited by applicant]
Yung-Chi, C. et al. (1973). Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (150) of an enzymatic reaction.
[cited by applicant]
Zhou, J. et al. (2010). Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer's disease.
[cited by applicant]
Zuccato, C. et al. (2009). Brain-derived neurotrophic factor in neurodegenerative diseases.
[cited by applicant]